The agency gave emergency use authorization to the Laboratory Corporation of America, or LabCorp, for its at-home COVID-19 test.
Patients must receive a physician’s order to obtain the test, which consists of nasal swabs and saline. Patients can collect nasal samples themselves and mail them to LabCorp for results.
LabCorp said it plans to make the test kits available in most states.
The FDA warned that its OK isn’t a general authorization for at-home collection of patient samples, only for LabCorp’s test.
Read the full news release here.
More articles on supply chain:
COVID-19 testing in the US: Where we started, where we are now
FDA approves new type of swab for COVID-19 testing
China’s export limits keeping medical supplies from reaching US
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.